Breaking News

MethylGene Makes Management Changes

March 15, 2013

Besterman, Baum and Gergen assume new roles

Jeffrey M. Besterman, Ph.D., has been appointed executive vice president of R&D and chief scientific officer at MethylGene, Inc. Joe Walewicz, vice president of business and corporate development, and Klaus B. Kepper, vice president finance and chief financial officer, will be leaving the company.
 
Dr. Charles Baum, chief executive officer, will take over Dr. Besterman’s responsibilities and Mark Gergen, chief operating officer has assumed the responsibilities of Mr. Kepper and Mr. Walewicz. 
 
"I want to personally thank Klaus, Jeff and Joe for their contributions to MethylGene," said Dr. Baum. “We wish them the best in their future pursuits.”
  • Packaging Equipment Technology Preview

    Packaging Equipment Technology Preview

    February 15, 2017
    Today’s complex drug products present challenges; the latest equipment capabilities help overcome them

  • The Good, the Bad, and the Donald

    The Good, the Bad, and the Donald

    January 31, 2017
    Orphan drugs, CMO continuous manufacturing and developing world sales offer biggest revenue opportunities

  • Predictive Analytics and the Future of RBM

    Rajneesh Patil, Senior Director, RBM and Analytics, QuintilesIMS||January 23, 2017
    How advances in Risk-Based Monitoring will enable a more proactive approach to identify and mitigate potential risks